Captopril
- Generic Name
- Captopril
- Drug Type
- Small Molecule
- Chemical Formula
- C9H15NO3S
- CAS Number
- 62571-86-2
- Unique Ingredient Identifier
- 9G64RSX1XD
- Background
Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment of hypertension.
- Indication
For the treatment of essential or renovascular hypertension (usually administered with other drugs, particularly thiazide diuretics). May be used to treat congestive heart failure in combination with other drugs (e.g. cardiac glycosides, diuretics, β-adrenergic blockers). May improve survival in patients with left ventricular dysfunction following myocardial infarction. May be used to treat nephropathy, including diabetic nephropathy.
- Associated Conditions
- Aldosteronism, Anatomic renal artery stenosis, Congestive Heart Failure (CHF), Diabetic Nephropathy, Heart Failure, Hypertension, Hypertensive crisis, Non-STEMI Acute Coronary Syndrome, Raynaud's Phenomenon, Ejection fraction of 40% or less Left ventricular dysfunction
Captopril Use on the Degree of Marrow Fibrosis in Bone Marrow Fibrosis/Myeloproliferative Neoplasms
- Conditions
- Bone Marrow FibrosisMyeloproliferative Neoplasm
- Interventions
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- Case Comprehensive Cancer Center
- Registration Number
- NCT04629651
- Locations
- 🇺🇸
Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Metformin Versus Vildagliptin in Reducing Risk of Metabolic Syndrome Complications Progression
- Conditions
- Metabolic SyndromeDiabete Type 2Kidney Insufficiency
- Interventions
- First Posted Date
- 2020-07-24
- Last Posted Date
- 2020-07-24
- Lead Sponsor
- Cairo University
- Target Recruit Count
- 39
- Registration Number
- NCT04485845
- Locations
- 🇪🇬
National Diabetes & Endocrinology Institute, Cairo, Egypt
Efficacy of Captopril in Covid-19 Patients With Severe Acute Respiratory Syndrome (SARS) CoV-2 Pneumonia (CAPTOCOVID)
- First Posted Date
- 2020-04-21
- Last Posted Date
- 2020-04-28
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 230
- Registration Number
- NCT04355429
- Locations
- 🇫🇷
Hôpital Avicenne, Bobigny, France
🇫🇷CH Victor Dupuy- Argenteuil, Argenteuil, France
🇫🇷Hôpital Antoine Béclère, Clamart, France
Evaluation of the Efficacy of Captopril Versus Propranolol and Timolol as a Treatment of Infantile Capillary Hemangioma
- Conditions
- Infantile Hemangioma
- Interventions
- First Posted Date
- 2020-02-28
- Last Posted Date
- 2020-02-28
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 100
- Registration Number
- NCT04288700
- Locations
- 🇪🇬
Vascular malformation clinic of Pediatric Surgery department of Ain Shams University., Cairo, Egypt
Prediction and Prevention of Asymptomatic Cardiovascular Insult in Type 1 Diabetic Children: Comparative Effectiveness of Cardioprotective Drugs
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2018-09-06
- Last Posted Date
- 2019-06-17
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 150
- Registration Number
- NCT03660293
- Locations
- 🇪🇬
Faculty of Medicine- Tanta University, Tanta, Gharbia, Egypt
The Role and Intervention of TGF-β in Abdominal Radiation Injury
- First Posted Date
- 2018-08-03
- Last Posted Date
- 2022-02-14
- Lead Sponsor
- Wuhan University
- Target Recruit Count
- 226
- Registration Number
- NCT03613506
- Locations
- 🇨🇳
Jin Peng, Wuhan, Hubei, China
Prevention of Chemotherapy Induced Cardiotoxicity in Children With Bone Tumors and Acute Myeloid Leukemia
- Conditions
- CardiotoxicityBone TumorAcute Myeloid Leukemia in Children
- Interventions
- First Posted Date
- 2018-01-04
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Children's Cancer Hospital Egypt 57357
- Target Recruit Count
- 245
- Registration Number
- NCT03389724
- Locations
- 🇪🇬
Children's Cancer Hospital Egypt 57357 Cairo, Egypt, Cairo, Egypt
Peripheral Vascular Effects of Sulfhydryl-containing Antihypertensive Pharmacotherapy on Microvessels in Humans
- Conditions
- Hypertension,Essential
- Interventions
- First Posted Date
- 2017-06-07
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Penn State University
- Target Recruit Count
- 10
- Registration Number
- NCT03179163
- Locations
- 🇺🇸
Pennsylvania State University, University Park, Pennsylvania, United States
Matão Controlling Hypertension (MatCH Study): Rationale and Design
- Conditions
- HypertensionBlood Pressure
- Interventions
- First Posted Date
- 2017-05-10
- Last Posted Date
- 2017-11-21
- Lead Sponsor
- Centro Neurológico de Pesquisa e Reabiitação, Brazil
- Target Recruit Count
- 15000
- Registration Number
- NCT03147092
A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma
- Conditions
- Glioblastoma
- Interventions
- First Posted Date
- 2016-05-12
- Last Posted Date
- 2021-10-05
- Lead Sponsor
- University of Ulm
- Target Recruit Count
- 10
- Registration Number
- NCT02770378
- Locations
- 🇩🇪
University of Ulm School of Medicine, Ulm, Baden-Württemberg, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.